Meeting
2016 ASCO Annual Meeting
Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC).
Authors
Rosa Berenato
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Rosa Berenato , Filippo Pietrantonio , Marta Caporale , Ilaria Bossi , Gianluca Tomasello , Stefania Mosconi , Emanuela Paterno , Silvia Bozzarelli , Raffaella Longarini , Stefania Gori , Alberto Zaniboni , Alessandro Stefano Bertolini , Francesca Bergamo , Sandro Barni , Alessio Amatu , Daniele Fagnani , M. Giulia Zampino , Federica Morano , Maria Di Bartolomeo , Filippo G. De Braud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02414009
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS3635)
DOI
10.1200/JCO.2016.34.15_suppl.TPS3635
Abstract #
TPS3635
Poster Bd #
326b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy.
First Author: Margaret Lee
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell
Poster
2012 Gastrointestinal Cancers Symposium
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of t-CORE0901.
First Author: Makio Gamoh
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang